Melanotan I vs Melanotan II for Research

Melanotan I and
Melanotan II are structurally different alpha-MSH analogues.
Melanotan I is the name historically associated with
[Nle4,D-Phe7]-alpha-MSH, now known as afamelanotide: a linear,
13-residue peptide analogue. Melanotan II is a shorter cyclic lactam
analogue built around the central melanocortin pharmacophore.

For research
procurement and analytical review, linear versus cyclic architecture,
sequence length, terminal chemistry, expected mass and batch-specific
HPLC/MS evidence are more reliable comparison anchors than
“stronger,” “better” or benefit-based descriptions.

Figure
1. Melanotan I versus Melanotan II research matrix comparing linear
13-residue and cyclic shortened peptide architecture, terminal
chemistry and analytical verification.

Quick comparison

Attribute	Melanotan I / Afamelanotide	Melanotan II
Architecture	Linear 13-residue alpha-MSH analogue	Shorter cyclic lactam alpha-MSH analogue
Common structural shorthand	[Nle4,D-Phe7]-alpha-MSH	Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Receptor context	Current afamelanotide label: predominantly MC1R	Broad melanocortin receptor research ligand
Analytical identity	Full linear sequence/form + expected mass + MS	Cyclic form/sequence + expected mass + MS
Boundary	Drug-label facts do not transfer to RUO batches	Preclinical/clinical findings are not use instructions

Melanotan I / afamelanotide is a linear
13-residue analogue

The current Scenesse
label describes afamelanotide as a synthetic 13-amino-acid peptide
with the sequence
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. It is
structurally related to alpha-MSH but contains Nle4 and D-Phe7
substitutions.

Older research on
[Nle4,D-Phe7]-alpha-MSH established markedly increased potency and
prolonged activity in melanocyte model systems. Those observations
belong to the tested analogue and model; they should not be
translated into tanning recommendations or personal-use claims.

Melanotan II is a truncated cyclic lactam peptide

MT-II is a cyclic
peptide built around the melanocortin core and commonly described as
Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Cyclisation constrains
the peptide conformation and changes both its size and receptor
interaction profile relative to the linear 13-mer.

Because the
molecules differ substantially in architecture, an HPLC retention
time or a shared “melanotan” label cannot establish
interchangeability.

Receptor context differs, but assay details still
matter

Current regulated
afamelanotide labelling identifies predominant binding/agonism at
MC1R. MT-II is widely used as a broader melanocortin receptor tool
ligand, and primary receptor-subtype studies show that cyclic
melanocortin analogues can interact with MC1R, MC3R, MC4R and MC5R
with differing affinities.

This is a research
distinction, not a recommendation. Receptor potency values are
assay-dependent and should not be turned into a “choose MT-I for X,
MT-II for Y” consumer framework.

What analytical evidence should differentiate the
two

For Melanotan I,
verify the full linear sequence/form and expected mass. For MT-II,
verify the cyclic peptide identity and terminal chemistry. In both
cases, match HPLC and MS records to the same product and batch. A
high HPLC area percentage does not replace the identity check.

From Our Work: comparison follows the evidence
hierarchy

Core Research’s
approved batch-review workflow treats analytical evidence as a linked
set rather than as a single purity number. The review checks HPLC
purity/profile, MS identity, product and batch match, appearance,
labelled amount/content, water or moisture where applicable,
counter-ion information, document completeness and storage/handling
status. Analytical testing is produced by the manufacturer and/or
third-party laboratories; Core Research reviews that evidence. If a
meaningful mismatch remains unresolved, the batch is held while
clarification and/or a justified retest is requested. This does not
imply in-house analytical testing or laboratory accreditation.

Applied to Melanotan
I versus II, that means the page starts from chemical identity and
batch evidence and only then uses receptor literature as context. The
review does not accept a benefit-based label or a shared catalogue
family as evidence that two materials are equivalent.

Keep regulated afamelanotide separate from an RUO
product

Scenesse is a
regulated afamelanotide medicine with a defined formulation and
manufacturing controls. Its current label is a useful authoritative
source for the molecule’s sequence and receptor description. It
does not establish the identity, purity or suitability of an
independently supplied research material.

Frequently asked questions

Is Melanotan I the same as afamelanotide?

Historically,
Melanotan I refers to [Nle4,D-Phe7]-alpha-MSH, the peptide now known
as afamelanotide. A regulated afamelanotide medicine is still not
evidence that an independently supplied RUO batch is equivalent in
formulation or quality.

Is Melanotan II just a shorter Melanotan I?

No. MT-II is not
merely a truncated linear peptide; it is a cyclic lactam analogue
with a different architecture and receptor interaction profile.

Which one is more selective?

Current
afamelanotide labelling describes predominant MC1R activity, whereas
MT-II is used as a broader melanocortin receptor ligand. Exact
potency and selectivity depend on the assay system and should not be
converted into clinical-selection advice.

What proves the supplied material is MT-I or
MT-II?

Use the stated
sequence/form, expected molecular mass, mass-spectrometric identity,
method-specific HPLC profile and coherent batch documentation. A
product name alone is not sufficient.

Key takeaway

Melanotan I and II
are different peptide architectures: a linear 13-residue
afamelanotide/NDP-MSH analogue versus a shorter cyclic MT-II
scaffold. Laboratory comparison should preserve that identity
boundary and keep receptor literature separate from personal-use or
clinical claims.

References

1. Hadley ME, et al.
[Nle4,D-Phe7]-alpha-MSH: a superpotent melanotropin that
“irreversibly” activates melanoma tyrosinase. Endocr Res. PMID:
3009169. https://pubmed.ncbi.nlm.nih.gov/3009169/

2. FDA/DailyMed
SCENESSE label. Afamelanotide structure:
Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2;
current label identifies predominant MC1R agonism.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48

3. Prusis P, et al.
Three-dimensional molecular models of the hMC1R melanocortin
receptor: complexes with melanotropin peptide agonists. PMID:
9017363. https://pubmed.ncbi.nlm.nih.gov/9017363/

4. Schioth HB, et
al. Selectivity of cyclic [D-Nal7] and [D-Phe7] substituted MSH
analogues for the melanocortin receptor subtypes. Peptides. 1997.
PMID: 9357059. https://pubmed.ncbi.nlm.nih.gov/9357059/